Documentos clave

Ver Toda la documentación

Saltar a

SML0150

Tolcapone

Name: Tolcapone
Brand: SIGMA
Price: 76.6 EUR

≥98% (HPLC), Catechol-O-methyltransferase inhibitor, powder

Sinónimos:

3,4-Dihydroxy-4′-methyl-5-nitrobenzophenone, Ro 40-7592

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Talla/SKU	Disponibilidad	Precio
10 mg	Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad	76,60 €
50 mg	Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad	297,00 €

Acerca de este artículo

Fórmula empírica (notación de Hill):

C₁₄H₁₁NO₅

Número CAS:

134308-13-7

Peso molecular:

273.24

UNSPSC Code:

12352200

PubChem Substance ID:

329825198

NACRES:

NA.77

MDL number:

MFCD00866569

Assay:

≥98% (HPLC)

Form:

powder

Storage condition:

desiccated

76,60 €

Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad

Solicita un pedido personalizado

Servicio técnico

¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.

Permítanos ayudarle

Propiedades

Nombre del producto

Tolcapone, ≥98% (HPLC)

Quality Segment

100

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

yellow

solubility

DMSO: ≥15 mg/mL

originator

Roche

storage temp.

2-8°C

SMILES string

Cc1ccc(cc1)C(=O)c2cc(O)c(O)c(c2)[N+]([O-])=O

InChI

1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3

InChI key

MIQPIUSUKVNLNT-UHFFFAOYSA-N

Gene Information

human ... COMT(1312)

Descripción

Application

Tolcapone may be used in COMT-mediated cell signaling studies.
Tolcapone has been used in methyltransferase assay in human embryonic kidney 293 cells.

Biochem/physiol Actions

Orally active catechol-O-methyltransferase (COMT) inhibitor: inhibits both central and peripheral COMT.

Tolcapone is an orally active catechol-O-methyltransferase (COMT) inhibitor. It inhibits both central and peripheral COMT. Tolcapone crosses the blood-brain barrier, and has been used for L-DOPA adjunct therapy in the treatment of Parkinson′s Disease.

Inhibition of catechol-O-methyltransferase by tolcapone increases the half-life and bioavailabilty of levodopa. It therefore is an effective adjunctive therapy in patients with Parkinson′s disease with motor response fluctuations.

Features and Benefits

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Comparar elementos similares

Ver comparación completa

Mostrar Diferencias

1 of 1

Este artículo	1670207	T7080	R108
Sigma-Aldrich SML0150 Tolcapone	USP 1670207 Tolcapone	Sigma-Aldrich T7080 Tazarotene	Sigma-Aldrich R108 Ro 41-0960
description ≥98% (HPLC)	description United States Pharmacopeia (USP) Reference Standard	description ≥98% (HPLC)	description solid
assay ≥98% (HPLC)	assay -	assay ≥98% (HPLC)	assay -
form powder	form -	form powder	form solid
Quality Level 100	Quality Level -	Quality Level 100	Quality Level 100
storage temp. 2-8°C	storage temp. -	storage temp. 2-8°C	storage temp. 2-8°C
solubility DMSO: ≥15 mg/mL	solubility -	solubility DMSO: >15 mg/mL	solubility H₂O: slightly soluble <0.7 mg/mL, ethanol: soluble, 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 1.0 mg/mL
storage condition desiccated	storage condition -	storage condition -	storage condition protect from light

Still not finding the right product?

Explore all of our products under Tolcapone

pictograms

GHS09

signalword

Warning

hcodes

H400

pcodes

P273 - P391 - P501

Hazard Classifications

Aquatic Acute 1

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c